keyword
MENU ▼
Read by QxMD icon Read
search

myeloma pet

keyword
https://www.readbyqxmd.com/read/29667156/how-we-manage-patients-with-plasmacytomas
#1
REVIEW
Despina Fotiou, Meletios A Dimopoulos, Efstathios Kastritis
PURPOSE OF REVIEW: To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM). RECENT FINDINGS: Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci...
April 17, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29620592/fluorodeoxyglucose-positron-emission-tomography-computed-tomography-in-amyloid-arthropathy-associated-to-multiple-myeloma
#2
Aida Sabaté-Llobera, Elena Llinares, Rolando Vallansot, Julieta Landeyro, Cristina Gámez-Cenzano
No abstract text is available yet for this article.
March 19, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29610955/prognostic-value-of-18-f-fdg-pet-ct-in-multiple-myeloma-patients-before-and-after-allogeneic-hematopoietic-cell-transplantation
#3
Antje Stolzenburg, Katharina Lückerath, Samuel Samnick, Martin Speer, Katharina Kneer, Jan-Stefan Schmid, Götz Ulrich Grigoleit, Susanne Hofmann, Ambros J Beer, Donald Bunjes, Stefan Knop, Andreas K Buck, Hermann Einsele, Constantin Lapa
PURPOSE: Despite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using18 F-2'-deoxy-2'-fluorodeoxyglucose ([18 F]FDG) in MM patients shortly before and ~100 days after allogeneic hematopoietic cell transplantation (allo-HCT). METHODS: In this retrospective analysis, we evaluated [18 F]FDG-PET/CT-scans of 45 heavily pre-treated MM patients before and 27 patients after scheduled allo-HCT...
April 2, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29597141/preliminary-evaluation-of-18-f-labeled-llp2a-trifluoroborate-conjugates-as-vla-4-%C3%AE-4-%C3%AE-1-integrin-specific-radiotracers-for-pet-imaging-of-melanoma
#4
Áron Roxin, Chengcheng Zhang, Sungjoon Huh, Mathieu L Lepage, Zhengxing Zhang, Kuo-Shyan Lin, François Bénard, David M Perrin
INTRODUCTION: The transmembrane α4 β1 integrin receptor, or very-late antigen 4 (VLA-4), is associated with tumor metastasis and angiogenesis, the development of chemotherapeutic drug resistance, and is overexpressed in multiple myelomas, osteosarcomas, lymphomas, leukemias, and melanomas. The peptidomimetic, LLP2A, is a high-affinity ligand with specificity for the extracellular portion of VLA-4 and several conjugates have been evaluated in vivo by NIR-fluorescence,111 In-SPECT and68 Ga- and64 Cu-PET imaging, but to date, not with18 F-PET...
March 12, 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29567784/treatment-to-suppression-of-focal-lesions-on-positron-emission-tomography-computed-tomography-is-a-therapeutic-goal-in-newly-diagnosed-multiple-myeloma
#5
Faith E Davies, Adam Rosenthal, Leo Rasche, Nathan M Petty, James E McDonald, James A Ntambi, Doug M Steward, Susan B Panozzo, Frits van Rhee, Maurizio Zangari, Carolina D Schinke, Sharmilan Thanendrarajan, Brian Walker, Niels Weinhold, Bart Barlogie, Antje Hoering, Gareth J Morgan
Fluorine-18 fluorodeoxyglucose positron emission tomography with CT attenuation correction (PET-CT) in myeloma can detect and enumerate focal lesions by the quantitative characterization of metabolic activity. The aim of this study was to determine the prognostic significance of the suppression of PET-CT activity at a number of time points post therapy initiation including day 7, post-induction, post-transplant and at maintenance therapy. As part of the TT4-6 trial series, 596 patients underwent baseline PET-CT and were evaluated serially during their disease course using peak standardized uptake values above background red marrow signal...
March 22, 2018: Haematologica
https://www.readbyqxmd.com/read/29552435/plasmacytoma-of-the-skull-base-a-rare-tumor
#6
Abhilasha Siyag, Tej P Soni, Anil K Gupta, Lalit M Sharma, Naresh Jakhotia, Shantanu Sharma
Plasmacytoma of the skull-base is a rare entity. Differential diagnosis includes chordoma, osteosarcoma, carcinoma nasopharynx, meningioma, metastatic carcinoma, lymphoma, and multiple myeloma. Accurate and precise diagnosis is extremely important for plasmacytoma of the skull-base as its treatment and prognosis is different from other skull-base lesions. A 41-year-old man presented with concerns of headache, diplopia, and left eye strabismus. A magnetic resonance image (MRI) of his brain showed a large expansile mass measuring 51 mm involving the clivus and central skull-base...
January 15, 2018: Curēus
https://www.readbyqxmd.com/read/29548488/comparison-of-whole-body-magnetic-resonance-imaging-wbmri-to-whole-body-computed-tomography-wbct-or-18-f-fluorodeoxyglucose-positron-emission-tomography-ct-18-f-fdg-pet-ct-in-patients-with-myeloma-systematic-review-of-diagnostic-performance
#7
REVIEW
Joanna Gariani, Olwen Westerland, Sarah Natas, Hema Verma, Gary Cook, Vicky Goh
OBJECTIVES: To undertake a systematic review to determine the diagnostic performance of whole body MRI (WBMRI) including diffusion weighted sequences (DWI) compared to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography/CT (18 F-FDG PET/CT) in patients with myeloma. METHODS: Two researchers searched the primary literature independently for WBMRI studies of myeloma. Data were extracted focusing on the diagnostic ability of WBMRI versus WBCT and 18 F-FDG PET/CT...
April 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29538035/multiple-myeloma-presenting-as-a-superscan-on-68ga-pentixafor-pet-ct
#8
Qingqing Pan, Yaping Luo, Xinxin Cao, Yanru Ma, Fang Li
A 60-year-old woman diagnosed with multiple myeloma was referred for Ga-pentixafor PET/CT for evaluation of the disease. Diffuse and intense radioactivity throughout the axial and proximal appendicular skeleton was noted on PET/CT images, suggestive of extensive involvement of multiple myeloma.
March 13, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29531504/automated-whole-body-bone-lesion-detection-for-multiple-myeloma-on-68-ga-pentixafor-pet-ct-imaging-using-deep-learning-methods
#9
Lina Xu, Giles Tetteh, Jana Lipkova, Yu Zhao, Hongwei Li, Patrick Christ, Marie Piraud, Andreas Buck, Kuangyu Shi, Bjoern H Menze
The identification of bone lesions is crucial in the diagnostic assessment of multiple myeloma (MM).68 Ga-Pentixafor PET/CT can capture the abnormal molecular expression of CXCR-4 in addition to anatomical changes. However, whole-body detection of dozens of lesions on hybrid imaging is tedious and error prone. It is even more difficult to identify lesions with a large heterogeneity. This study employed deep learning methods to automatically combine characteristics of PET and CT for whole-body MM bone lesion detection in a 3D manner...
2018: Contrast Media & Molecular Imaging
https://www.readbyqxmd.com/read/29507674/comparison-of-immuno-pet-of-cd138-and-pet-imaging-with-64-cucl-2-and-18-f-fdg-in-a-preclinical-syngeneic-model-of-multiple-myeloma
#10
Clément Bailly, Sébastien Gouard, Marie Lacombe, Patricia Remaud-Le Saëc, Benjamin Chalopin, Mickaël Bourgeois, Nicolas Chouin, Raphaël Tripier, Zakaria Halime, Ferid Haddad, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré, Michel Chérel, Caroline Bodet-Milin
Purpose: Although recent data from the literature suggest that PET imaging with [18]-Fluorodeoxyglucose (18 F-FDG) is a promising technique in multiple myeloma (MM), the development of other radiopharmaceuticals seems relevant. CD138 is currently used as a standard marker in many laboratories for the identification and purification of myeloma cells, and could be used in phenotype tumor imaging. In this study, we evaluated a64 Cu-labeled anti-CD138 murine antibody (64 Cu-TE2A-9E7.4) and a metabolic tracer (64 CuCl2 ) for PET imaging in a MM syngeneic mouse model...
February 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/29450576/immunopet-imaging-of-cd38-in-murine-lymphoma-models-using-89-zr-labeled-daratumumab
#11
Lei Kang, Dawei Jiang, Christopher G England, Todd E Barnhart, Bo Yu, Zachary T Rosenkrans, Rongfu Wang, Jonathan W Engle, Xiaojie Xu, Peng Huang, Weibo Cai
PURPOSE: CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with89 Zr-labeled daratumumab was used for differentiation of CD38 expression in murine lymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic...
February 15, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29431555/current-concepts-in-tumor-imaging-with-whole-body-mri-with-diffusion-imaging-wb-mri-dwi-in-multiple-myeloma-and-lymphoma
#12
Alessandro Stecco, Francesco Buemi, Antoine Iannessi, Alessandro Carriero, Andrea Gallamini
Whole-body MRI (WB-MRI) with diffusion-weighted imaging (DWI) can now be used to stage and restage multiple myeloma (MM) and lymphoma. Magnetic resonance imaging (MRI) is the standard tool to detect BM involvement (BMI). The 2016 diagnostic criteria of the International Myeloma Working Group identify WB-MRI and fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as the most sensitive imaging techniques for detecting skeletal and extra-skeletal MM invasion, respectively. Preliminary findings have also shown that WB-MRI is better than CT and equal to PET/CT in staging aggressive lymphoma and Hodgkin lymphoma, whereas MRI is better for diagnosing BMI in patients with low-grade lymphoma...
February 12, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29340123/multiple-extramedullary-plasmacytoma-in-a-setting-of-complete-bone-marrow-remission-food-for-thought
#13
Negi Preety, Kingsley Pamela Alice, Jomi Chinnu, Mathew Amrith, George Sneha, Immanuel Vivek, Abraham Puliyelil Abraham
Extramedullary plasmacytoma as a mode of relapse in multiple myeloma (MM) is unusual. Current recommendations do not incorporate the routine use of 18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) imaging prior to haematopoietic stem cell transplant (HSCT) in MM. We report a case of relapsed MM with complete remission as per IMWG criteria. In the interim period, before the HSCT, the patient had localizing neurological signs and symptoms attributed to multiple extramedullary plasmacytomas...
October 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/29338789/diagnosis-treatment-and-response-assessment-in-solitary-plasmacytoma-updated-recommendations-from-a-european-expert-panel
#14
REVIEW
J Caers, B Paiva, E Zamagni, X Leleu, J Bladé, S Y Kristinsson, C Touzeau, N Abildgaard, E Terpos, R Heusschen, E Ocio, M Delforge, O Sezer, M Beksac, H Ludwig, G Merlini, P Moreau, S Zweegman, M Engelhardt, L Rosiñol
Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography-computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions...
January 16, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29315287/monitoring-multiple-myeloma
#15
Kyle A Udd, Tanya M Spektor, James R Berenson
Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation in bone marrow of terminally differentiated plasma cells. MM is a slowly growing, heterogeneous disease with no known cure. Patients with MM have a median survival of approximately 5 years, during which they may experience significant morbidity. More reliable and rapid determination of changes in the clinical status of patients with MM is becoming increasingly important because of the increasing number of available treatments for these patients...
December 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29301755/copper-64-labeled-daratumumab-as-a-pet-ct-imaging-tracer-for-multiple-myeloma
#16
Enrico Caserta, Junie Chea, Megan Minnix, Domenico Viola, Steven Vonderfecht, Paul Yazaki, Desiree Crow, Jihane Khalife, James F Sanchez, Joycelynne M Palmer, Susanta Hui, Nadia Carlesso, Jonathan Keats, Young Kim, Ralf Buettner, Guido Marcucci, Steven Rosen, John Shively, David Colcher, Amrita Krishnan, Flavia Pichiorri
As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often unpredictable, attention has increasingly focused on developing novel diagnostic criteria to also account for disease dissemination. Positron emission tomography/computed tomography (PET/CT) is often used as a noninvasive monitoring strategy to assess cancer cell dissemination, but because the uptake of the currently used radiotracer 18fluorodeoxyglucose (18 F-FDG) is a function of the metabolic activity of both malignant and nonmalignant cells, the results frequently lack sufficient specificity...
February 15, 2018: Blood
https://www.readbyqxmd.com/read/29244720/functional-imaging-with-18-f-fdg-pet-ct-and-diffusion-weighted-imaging-dwi-in-early-response-evaluation-of-combination-therapy-of-elotuzumab-lenalidomide-and-dexamethasone-in-a-relapsed-multiple-myeloma-patient
#17
Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme, Hartmut Goldschmidt
Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesions on imaging modalities, who was started on a combination treatment of elotuzumab, lenalidomide, and dexamethasone. After completion of three cycles of the new therapy the patient responded very well with a major decline of serological myeloma activity parameters serum monoclonal protein, kappa light chains, free light chains (FLC) ratio...
December 15, 2017: Diagnostics
https://www.readbyqxmd.com/read/29226428/predictive-value-of-18-f-fdg-pet-ct-scanning-in-combination-with-clinical-parameters-in-patients-with-newly-diagnosed-multiple-myeloma
#18
Honglei Tu, Yong He, Tianhe Huang, Songguk Choe, Xiaoli Lan, Xiaoyi Duan, Haseeb Sattar, Chongjiao Li, Fuling Zhou
OBJECTIVE: To evaluate the association of18 F-2'-deoxy 2'-fluorodeoxyglucose (18 F-FDG) PET/CT with clinical parameters in predicting patients with newly diagnosed multiple myeloma (MM). METHODS: A total of 120 MM patients undergoing18 F-FDG PET/CT scanning were analyzed in a retrospective cohort study. RESULTS: Based on multivariate analysis, β2M, LDH, number of focal lesions (FLs), and SUVmax were significantly correlated with OS. These 4 variables were used to construct a new staging system (NSS) based on the number of risk factors...
February 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29182106/multidisciplinary-approach-to-osteosarcoma
#19
REVIEW
A Biazzo, M De Paolis
Osteosarcoma is a malignant bone tumor composed of mesenchymal cells producing osteoid and immature bone. Osteosarcoma is the most frequent primary malignant bone tumor, if we excluded myeloma, a haematologic disease. The incidence of osteosarcoma is 2-3/million/year, but is higher in adolescence, in which the annual incidence peaks at 8-11/million/year at 15-19 years of age. Local pain, followed by localized swelling and limitation of joint movement, are the typical signs and symptoms. Correct diagnosis can be achieved through a correct approach to the disease and the combination of clinical and radiographic aspects...
December 2016: Acta Orthopaedica Belgica
https://www.readbyqxmd.com/read/29179894/-preventative-and-therapeutic-relapse-strategies-after-allogeneic-hematopoietic-stem-cell-transplantation-guidelines-from-the-francophone-society-of-bone-marrow-transplantation-and-cellular-therapy-sfgm-tc
#20
REVIEW
Nabil Yafour, Florence Beckerich, Claude Eric Bulabois, Patrice Chevallier, Étienne Daguindau, Cécile Dumesnil, Thierry Guillaume, Anne Huynh, Stavroula Masouridi Levrat, Anne-Lise Menard, Mauricette Michallet, Cécile Pautas, Xavier Poiré, Aurelie Ravinet, Ibrahim Yakoub-Agha, Ali Bazarbachi
Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT). The risk of recurrence is elevated in patients with high-risk cytogenetic or molecular abnormalities, as well as when allo-HCT is performed in patients with refractory disease or with persistent molecular or radiological (PET-CT scan) residual disease. Within the frame of the 7th annual workshops of the francophone society for bone marrow transplantation and cellular therapy, the working group reviewed the literature in order to elaborate unified guidelines for the prevention and treatment of relapse after allo-HCT...
December 2017: Bulletin du Cancer
keyword
keyword
96974
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"